NSE · TATVA
Tatva Chintan Pharma Chem Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹147 Cr with net profit ₹10 Cr — a 7.12% net margin, versus 8.26% the period before.
Shareholding
As of 2026-06-30
- Promoter72.02%
- Public20.94%
- FII3.93%
- DII3.11%
64,921 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.88× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Chemicals · ranked #40 of 159 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Solar Industries India Ltd. | ₹2,02,426 Cr | 101.65 | 32.28 | 26.72% | 17.54% |
| Pidilite Industries Ltd. | ₹1,59,705 Cr | 60.3 | 14.74 | 22.61% | 17.2% |
| SRF Ltd. | ₹74,669 Cr | 33.32 | 5.29 | 13.07% | 13.01% |
| Linde India Limited | ₹53,111 Cr | 97.2 | 12.45 | 12.87% | 20.59% |
| Gujarat Fluorochemicals Ltd. | ₹52,578 Cr | 85.12 | 6.76 | 7.13% | 11.41% |
| Navin Fluorine International Ltd. | ₹44,646 Cr | 56.14 | 11.23 | 16.69% | 21.73% |
| Godrej Industries Ltd. | ₹37,805 Cr | 30.9 | 3.39 | 11.1% | 5.06% |
| Himadri Speciality Chem Limited | ₹33,491 Cr | 41.9 | 7.12 | 15.96% | 16.07% |
| Deepak Nitrite Ltd. | ₹22,448 Cr | 28.34 | 3.85 | 9.43% | 9.13% |
| Aether Industries Limited | ₹21,771 Cr | 90.72 | 8.88 | 8.94% | 19.11% |
| Tatva Chintan Pharma Chem Ltd.(this company) | ₹3,881 Cr | 74.1 | 4.98 | 5.38% | 9.24% |
AI analysis
AI-generated · google/gemini-2.5-flashTatva Chintan Pharma Chem Ltd. is listed with a market capitalization of Rs 3942 Cr. The company reported revenue of Rs 385.03 Cr. The latest annual EPS is Rs 2.44.
Positives
- +The debt-to-equity ratio is low at 0.03.
- +Promoter holding of 72.02% as of June 30, 2026.
- +No promoter shares are pledged (0%).
Negatives
- −The trailing twelve months PE ratio is high at 278.26.
- −The Return on Equity (ROE) is low at 0.8%.
- −Return on Capital Employed (ROCE) is low at 6.63%.
- −Promoter holding has decreased from 79.17% in December 2022 to 72.02% in June 2026.
- −The company is under 'ST-ASM · ASM 1' surveillance.
Financial performance
The company's revenue for the fiscal year ended March 2026 was Rs 132.67 Cr, with a net profit of Rs 9.02 Cr. In the subsequent quarter ending June 2026, revenue increased to Rs 146.7 Cr and net profit rose to Rs 10.45 Cr. Quarterly revenue for the period ending June 2026 was Rs 167.06 Cr, generating a net profit of Rs 15.98 Cr, compared to Rs 134.14 Cr revenue and Rs 10.32 Cr net profit in the March 2026 quarter.
Profitability & returns
Tatva Chintan Pharma Chem Ltd. recorded a Return on Equity (ROE) of 0.8% and a Return on Capital Employed (ROCE) of 6.63%. The Earnings Per Share (EPS) stands at Rs 2.44.
Balance sheet
The debt-to-equity ratio for the company is low at 0.03, indicating a low reliance on debt financing. The book value per share is Rs 315.84.
Ownership & pledges
As of June 30, 2026, promoters held 72.02% of the shares, with no shares pledged. Foreign Institutional Investors (FIIs) held 3.93% and Domestic Institutional Investors (DIIs) held 3.11%. Public shareholding was 20.94%. The total number of shareholders was 64,921.
Regulatory & surveillance
The company is under 'ST-ASM · ASM 1' surveillance, specifically noted for 'ST-ASM' measures, suggesting enhanced monitoring by regulatory bodies.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Tatva Chintan Pharma Chem Ltd.share price & fundamentals